Recent Tuberculosis Current Events | Tuberculosis News
|
| Page
1 of
10 |
198 Results |
|
|
|
Sort By:
Relevance | Page Views |
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. view more (2009-11-12)
Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. view more (2009-10-27)
Iowa State University researcher uncovers potential key to curing tuberculosis
Researchers at Iowa State University have identified an enzyme that helps make tuberculosis resistant to a human's natural defense system. Researchers have also found a method to possibly neutralize that enzyme, which may someday lead to a cure for tuberculosis. view more (2009-10-02)
New test quickly ID's active TB in smear-negative patients
Active tuberculosis can be rapidly identified in patients with negative sputum tests by a new method, according to European researchers. Active tuberculosis (TB) is the seventh-leading cause of death worldwide, and while the diagnosis of active TB can be rapidly established when the bacteria can be identified on sputum microscopy, in about half of... view more... (2009-09-23)
MUHC/McGill researchers to WHO: Time to revise tuberculosis treatment guidelines
Tuberculosis is a global threat that affects more than 10 million people each year. Working with colleagues in the United States and France, Dr. Dick Menzies of the Research Institute of the McGill University Health Centre (RI-MUHC) has placed current tuberculosis treatment guidelines under the microscope in a new study. view more (2009-09-15)
UAB Researchers Find TB-Prevention Therapy Is Cost-Effective Option
University of Alabama at Birmingham (UAB) researchers have found that the cost of preventive antibiotic tuberculosis (TB) therapy for patients infected by human immunodeficiency virus (HIV) is generally less expensive than the reported cost of treating newly confirmed TB cases. view more (2009-09-10)
Scientific community urges officials and public to use latest evidence as guide in H1N1 prevention and protection procedures
As flu season draws nearer along with the potential for resurgence in H1N1, leading infectious diseases doctors, hospital epidemiologists, and infection preventionists urge officials to base recommendations for the public and healthcare workers on scientific knowledge and frontline experience gained from the outbreak this summer. view more (2009-08-12)
Misuse of common antibiotic is creating resistant TB
Use of a common antibiotic may be undercutting its utility as a first-line defense against drug-resistant tuberculosis (TB). Fluoroquinolones are the most commonly prescribed class of antibiotics in the U.S. and are used to fight a number of different infections such as sinusitis and pneumonia. view more (2009-08-11)
Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report
The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said. view more (2009-07-30)
Resistance to antibiotics: When 1+1 is not 2
The evolution of multiple antibiotic resistances is a global and difficult problem to eradicate. view more (2009-07-24)
Scientists from Scotland to Sweden Arrive at NIMBioS to Study Bovine TB
In 2008, the U.S. Department of Agriculture spent $31 million to depopulate herds of cattle affected by bovine tuberculosis (TB), even though the risk of the disease has been significantly reduced in the U.S. over the past several decades. view more (2009-07-13)
One secret to how TB sticks with you
Mycobacterium tuberculosis is arguably the world's most successful infectious agent because it knows how to avoid elimination by slowing its own growth to a crawl. view more (2009-07-10)
Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection
A team of Harvard scientists has taken an important first step toward the development of new treatments to help people with HIV battle Mycobacterium tuberculosis (TB) infection. view more (2009-07-01)
Measurements fail to identify TB patients who could benefit from shorter treatment course
Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in resource-limited settings with poor public health infrastructures. view more (2009-07-01)
Carb synthesis sheds light on promising tuberculosis drug target
A fundamental question about how sugar units are strung together into long carbohydrate chains has also pinpointed a promising way to target new medicines against tuberculosis. view more (2009-06-23)
Unexpected discovery can open a new chapter in the fight against tuberculosis
A close relative of the microorganism that causes tuberculosis in humans has been found to form spores. view more (2009-06-09)
TB -- hiding in plain sight
Current research suggests that Mycobacterium tuberculosis can evade the immune response. view more (2009-05-22)
Study suggests TB screening needs to be targeted for maximum public health benefit
New estimates of the likelihood that a latent case of tuberculosis (TB) will become active have resulted in a roughly 50 percent increase over previous estimates of the number of people needed to be screened (NNS) to prevent an active infection, limiting the cost effectiveness of screening in many Center for Disease Control and Prevention... view more... (2009-05-20)
Gains in access to antiretroviral treatment come with some costs
In this week's PLoS Medicine magazine, Yibeltal Assefa, from the National HIV/AIDS Prevention and Control Office in Addis Ababa, and colleagues describe the successes and challenges of the scale-up of antiretroviral treatment (ART) across Ethiopia. view more (2009-04-28)
Rifampin kinetics poor in children
Rifampin (RMP), a first-line antituberculosis drug, reaches serum concentrations well below suggested lower limits when a standard dose of 8-12mg/kg body weight is given to children. view more (2009-04-22)
|
|
| Page
1 of
10 |
198 Results |
|
|
|
Sort By:
Relevance | Page Views |
|
